Brief Primer on the Discovery of New Antifungal Drugs from Plant Sources

The antifungal armamentarium is shrinking while resistance to licensed agents rises. Historically, actinomycetes and fungi delivered nystatin, amphotericin B, griseofulvin and the echinocandin scaffold, yet plant-derived compounds-despite potent in-vitro activity-have rarely reached the clinic.

To frame the recent in-vivo success of papaya-seed essential oil against fluconazole-sensitive and -resistant Candida albicans within the broader context of plant-based antifungal discovery, and to propose rigorous criteria that can accelerate translation, especially considering varying resource settings.

Commentary on Ma et al. (Mycopathologia 190(5):1-14, 2025) showing that benzyl-isothiocyanate-rich papaya-seed oil outperforms fluconazole in a murine systemic candidiasis model without acute toxicity; Historical perspective on how soil microbes provided the first broad-spectrum antifungals; An eight-point checklist for future plant-extract studies, with essential and suggested elements to promote high-quality research across different laboratory settings.

Adherence to core methodological standards, along with suggested advanced analyses where feasible, will help identify promising plant-derived antifungal leads and support a more inclusive and effective discovery pipeline.